The study of ANCA for efficacy of biologics therapy in patients with ulcerative colitis

The study of anti-neutrophil cytoplasmic antibody(ANCA) for efficacy of biologics therapy in patients with ulcerative colitis - The study of ANCA for efficacy of biologics therapy in patients with ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043883

Enrollment

200

Registered

2021-04-10

Start date

2021-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) UC patients who plan to receive biologics (2) Persons who have obtained written consent to participate in the research (3) Gender does not matter (4) Persons who are 16 years of age or older at the time of obtaining consent

Exclusion criteria

Exclusion criteria: (1) Persons who did not obtain consent after the explanation (2) Those who cannot get an understanding by explaining it verbally (3) Persons who have already been administered biopharmacy at the time of obtaining consent (4) Partial Mayo score 2 points or less

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study is proportion of patients with primary non-response to biologics stratified by PR3-ANCA and MPO-ANCA positivity.	—

Secondary

Measure	Time frame
The secondary outcome of this study is proportion of patients with loss of response to biologics stratified by PR3-ANCA and MPO-ANCA positivity.	—

Countries

Japan

Contacts

Public Contactatsushi yoshida

Ofuna Chuo Hospital Center for Gastroenterology and Inflammatory Bowel Disease

atushi.y@kza.biglobe.ne.jp0467-45-2111

Outcome results